Wisconsin is currently home to 1261 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
GpCRC Pediatric Gastroparesis Registry 2
NCT05981300
Recruiting
The objective of the Pediatric Gastroparesis Registry 2 is to create a national prospective registry of children, adolescents, and young adults with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying).
Gender:
ALL
Ages:
Between 8 years and 25 years
Trial Updated:
07/03/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Gastroparesis, Gastroparesis-like Syndrome
Register for Updates
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
NCT05451771
Recruiting
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: AL Amyloidosis
Register for Updates
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995
Recruiting
In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary anti-tumor activity of two different doses/regimens of \[... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/02/2025
Locations: University Of Wisconsin, Madison, Wisconsin
Conditions: Breast Cancer
Register for Updates
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05267821
Recruiting
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Gender:
ALL
Ages:
Between 1 day and 17 years
Trial Updated:
07/02/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Register for Updates
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
NCT04310020
Recruiting
This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Ascension Saint Elizabeth Hospital, Appleton, Wisconsin
Conditions: Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma
Register for Updates
Validating Osteoporosis Detection in Rho AI Software
NCT06830005
Recruiting
To assess the effectiveness of 16bit's Rho AI (artificial intelligence) software at identifying known cases of osteoporosis. 800 de-identified images from January 2007 to January 2024 will be accessed to test the software prospectively.
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
07/01/2025
Locations: UW School of Medicine and Public Health, Madison, Wisconsin
Conditions: Osteopenia or Osteoporosis
Register for Updates
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
NCT06333015
Recruiting
This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/01/2025
Locations: Site 111, Mount Pleasant, Wisconsin
Conditions: Cataract
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Appleton, Wisconsin
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399
Recruiting
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/01/2025
Locations: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Register for Updates
Evaluation of the Neurologic Assessment in Pediatric Neuro-Oncology (pNANO)
NCT06981156
Recruiting
This study aims to investigate a neurologic exam scale to provide an objective and more standard way to assess tumor response in pediatric patients with brain and spinal cord tumors.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
06/30/2025
Locations: American Family Children's Hospital, Madison, Wisconsin
Conditions: Pediatric Brain Tumor, Pediatric Spine Tumor
Register for Updates
The Avenues Study: Dual Use Cessation
NCT06474299
Recruiting
The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/30/2025
Locations: University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin
Conditions: Smoking Cessation, Electronic Cigarette Use
Register for Updates
Comparison of Microglial Activation in Severe Asthma and Healthy Controls
NCT06299592
Recruiting
The goal of this clinical trial is to learn about how asthma influences brain function. The main questions it aims to answer are: * How airway inflammation in asthma affects the brain; and, * Whether airway inflammation in asthma is related to symptoms of depression and anxiety Over the course of 3 visits, participants will: * Complete questionnaires * Complete computer tasks * Undergo allergy skin test and breathing tests * Give two blood samples * Give a sputum sample * Complete brain imagi... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/30/2025
Locations: Center for Healthy Minds, Madison, Wisconsin
Conditions: Asthma
Register for Updates